Diurnal is focused on developing and commercialising rare disease therapies in the area of endocrinological diseases. We have a growing product pipeline, with multiple candidates in development.

Founded in 2004, DIURNAL® , a NEUROCRINE BIOSCIENCES® Company, is a European, UK-headquartered specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia, Adrenal Insufficiency, Hypogonadism and Hypothyroidism.
Our expertise and innovative research activities focus on circadian-based endocrinology (mimicking the body's natural hormone levels) to develop products for rare and chronic endocrine conditions
Partnering and business development is integral to our strategy of building a leading pharmaceutical company. We forge creative partnerships with other innovative companies that advance our business.
Effective 1 November 2022, Diurnal Limited has been acquired by Neurocrine Biosciences Inc
View all historical press releases in the News section. Effective 1 November 2022, Diurnal Limited has been acquired by Neurocrine Biosciences Inc.
Diurnal is a rapidly growing global specialty pharmaceutical company with a highly integrated and very committed team. We're always looking for talented individuals who share our vision.
Diurnal is focused on developing and commercialising rare disease therapies in the area of endocrinological diseases. We have a growing product pipeline, with multiple candidates in development.